These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 22587755)

  • 21. Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA Cooperative Study.
    Gelernter J; Gueorguieva R; Kranzler HR; Zhang H; Cramer J; Rosenheck R; Krystal JH;
    Alcohol Clin Exp Res; 2007 Apr; 31(4):555-63. PubMed ID: 17374034
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacogenetics of OPRM1.
    Crist RC; Berrettini WH
    Pharmacol Biochem Behav; 2014 Aug; 123():25-33. PubMed ID: 24201053
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The μ-opioid receptor and treatment response to naltrexone.
    Thorsell A
    Alcohol Alcohol; 2013; 48(4):402-8. PubMed ID: 23543091
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predicting the effect of naltrexone and acamprosate in alcohol-dependent patients using genetic indicators.
    Ooteman W; Naassila M; Koeter MW; Verheul R; Schippers GM; Houchi H; Daoust M; van den Brink W
    Addict Biol; 2009 Jul; 14(3):328-37. PubMed ID: 19523047
    [TBL] [Abstract][Full Text] [Related]  

  • 25. OPRM1 Moderates Daily Associations of Naltrexone Adherence With Alcohol Consumption: Preliminary Evidence From a Mobile Health Trial.
    Hendershot CS; Dermody SS; Wardell JD; Zaso MJ; Kennedy JL; Stoner SA
    Alcohol Clin Exp Res; 2020 Apr; 44(4):983-991. PubMed ID: 32020635
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Moderators of naltrexone's effects on drinking, urge, and alcohol effects in non-treatment-seeking heavy drinkers in the natural environment.
    Tidey JW; Monti PM; Rohsenow DJ; Gwaltney CJ; Miranda R; McGeary JE; MacKillop J; Swift RM; Abrams DB; Shiffman S; Paty JA
    Alcohol Clin Exp Res; 2008 Jan; 32(1):58-66. PubMed ID: 18028530
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Naltrexone modification of drinking effects in a subacute treatment and bar-lab paradigm: influence of OPRM1 and dopamine transporter (SLC6A3) genes.
    Anton RF; Voronin KK; Randall PK; Myrick H; Tiffany A
    Alcohol Clin Exp Res; 2012 Nov; 36(11):2000-7. PubMed ID: 22551036
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dopaminergic Genetic Variation Influences Aripiprazole Effects on Alcohol Self-Administration and the Neural Response to Alcohol Cues in a Randomized Trial.
    Schacht JP; Voronin KE; Randall PK; Anton RF
    Neuropsychopharmacology; 2018 May; 43(6):1247-1256. PubMed ID: 29362512
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Influence of the OPRM1 A118G polymorphism on alcohol-induced euphoria, risk for alcoholism and the clinical efficacy of naltrexone.
    Setiawan E; Pihl RO; Benkelfat C; Leyton M
    Pharmacogenomics; 2012 Jul; 13(10):1161-72. PubMed ID: 22909206
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A within-group design of nontreatment seeking 5-HTTLPR genotyped alcohol-dependent subjects receiving ondansetron and sertraline.
    Kenna GA; Zywiak WH; McGeary JE; Leggio L; McGeary C; Wang S; Grenga A; Swift RM
    Alcohol Clin Exp Res; 2009 Feb; 33(2):315-23. PubMed ID: 19032576
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting treatments for alcohol dependence: the pharmacogenetics of naltrexone.
    Oslin DW; Berrettini WH; O'Brien CP
    Addict Biol; 2006 Sep; 11(3-4):397-403. PubMed ID: 16961767
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The conditioning of intervention effects on early adolescent alcohol use by maternal involvement and dopamine receptor D4 (DRD4) and serotonin transporter linked polymorphic region (5-HTTLPR) genetic variants.
    Cleveland HH; Schlomer GL; Vandenbergh DJ; Feinberg M; Greenberg M; Spoth R; Redmond C; Shriver MD; Zaidi AA; Hair KL
    Dev Psychopathol; 2015 Feb; 27(1):51-67. PubMed ID: 25640830
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Different phenotypic and genotypic presentations in alcohol dependence: age at onset matters.
    Chen YC; Prescott CA; Walsh D; Patterson DG; Riley BP; Kendler KS; Kuo PH
    J Stud Alcohol Drugs; 2011 Sep; 72(5):752-62. PubMed ID: 21906503
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacogenetic treatments for drug addiction: alcohol and opiates.
    Haile CN; Kosten TA; Kosten TR
    Am J Drug Alcohol Abuse; 2008; 34(4):355-81. PubMed ID: 18584566
    [TBL] [Abstract][Full Text] [Related]  

  • 35. OPRM1 genotype and naltrexone response in depressed alcohol-dependent patients.
    Foulds JA; Ton K; Kennedy MA; Adamson SJ; Mulder RT; Sellman JD
    Pharmacogenet Genomics; 2015 May; 25(5):270-3. PubMed ID: 25715171
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preserved DNA from past clinical trials yields new information about a subtype of alcoholism.
    O'Brien CP
    Curr Psychiatry Rep; 2008 Oct; 10(5):375-6. PubMed ID: 18803909
    [No Abstract]   [Full Text] [Related]  

  • 37. An analysis of the effect of mu-opioid receptor gene (OPRM1) promoter region DNA methylation on the response of naltrexone treatment of alcohol dependence.
    Lin Y; Kranzler HR; Farrer LA; Xu H; Henderson DC; Zhang H
    Pharmacogenomics J; 2020 Oct; 20(5):672-680. PubMed ID: 32029903
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of molecular targets associated with ethanol toxicity and implications in drug development.
    Wang LL; Yang AK; He SM; Liang J; Zhou ZW; Li Y; Zhou SF
    Curr Pharm Des; 2010; 16(11):1313-55. PubMed ID: 20184550
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-Effectiveness Analysis of Genotype-Guided Treatment Allocation in Patients with Alcohol Use Disorders Using Naltrexone or Acamprosate, Using a Modeling Approach.
    Sluiter RL; Kievit W; van der Wilt GJ; Schene AH; Teichert M; Coenen MJH; Schellekens A
    Eur Addict Res; 2018; 24(5):245-254. PubMed ID: 30384381
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacotherapy for alcohol dependence: anticraving medications for relapse prevention.
    Jung YC; Namkoong K
    Yonsei Med J; 2006 Apr; 47(2):167-78. PubMed ID: 16642544
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.